VYTORIN® (ezetimibe/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study

Dateline City: CHICAGO CHICAGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the investigational IMPROVE-IT study met its primary and all secondary composite efficacy endpoints. Language: English Contact: MerckMedia Contact:Pam Eisele, 267-305-3558orInvestor Contact:Joe Romanelli, 908-423-5185 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news